Halia Therapeutics, a clinical-stage biopharmaceutical company developing medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, appointed Lisa Shamon, vice president regulatory affairs and Xianne Penny, senior medical director. Shamon has over 20 years of experience in the pharmaceutical biotechnology space, having led multiple programs through early- through late-stage development. She also has expertise in regulatory strategies and global interac...